ADC Therapeutics (ADCT) News Today $1.62 -0.04 (-2.12%) Closing price 03/25/2025 03:58 PM EasternExtended Trading$1.69 +0.08 (+4.64%) As of 03/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025March 25 at 5:30 PM | prnewswire.comADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on ...March 20, 2025 | gurufocus.comADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025March 20, 2025 | prnewswire.comADC Therapeutics SA (NYSE:ADCT) Shares Purchased by Platinum Investment Management Ltd.Platinum Investment Management Ltd. boosted its holdings in ADC Therapeutics SA (NYSE:ADCT - Free Report) by 11.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,612,556 shares of the company's stock after buying an additional 168,040 sMarch 20, 2025 | marketbeat.comADC Therapeutics (NYSE:ADCT) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of ADC Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comADC Therapeutics (ADCT) to Release Earnings on WednesdayADC Therapeutics (NYSE:ADCT) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comNewly launched Seattle cancer therapy startup Callio Therapeutics raises $187MMarch 4, 2025 | msn.comADC Therapeutics price target raised to $8 from $6 at StephensFebruary 24, 2025 | markets.businessinsider.comStephens Forecasts Strong Price Appreciation for ADC Therapeutics (NYSE:ADCT) StockStephens lifted their price target on ADC Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a research note on Monday.February 24, 2025 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Short Interest Down 6.2% in JanuaryADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,860,000 shares, a decrease of 6.2% from the January 15th total of 5,180,000 shares. Based on an average trading volume of 921,800 shares, the days-to-cover ratio is presently 5.3 days.February 18, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Stake in ADC Therapeutics SAFebruary 15, 2025 | gurufocus.comADCT stock touches 52-week low at $1.42 amid market challengesFebruary 12, 2025 | msn.comADCT Stock Touches 52-Week Low at $1.61 Amid Market ChallengesJanuary 30, 2025 | msn.comADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | prnewswire.comADCT stock touches 52-week low at $1.66 amid market challengesJanuary 23, 2025 | msn.comEquities Analysts Issue Forecasts for ADCT FY2025 EarningsADC Therapeutics SA (NYSE:ADCT - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ADC Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($1.66) perJanuary 22, 2025 | marketbeat.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Expands By 18.0%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 4,860,000 shares, an increase of 18.0% from the December 15th total of 4,120,000 shares. Based on an average daily trading volume, of 865,500 shares, the days-to-cover ratio is currently 5.6 days.January 19, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT)HC Wainwright reissued a "buy" rating and set a $8.00 price objective on shares of ADC Therapeutics in a research note on Monday.January 6, 2025 | marketbeat.comIs ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value?January 3, 2025 | sg.finance.yahoo.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanJanuary 2, 2025 | prnewswire.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 36.9%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 4,120,000 shares, a growth of 36.9% from the November 30th total of 3,010,000 shares. Based on an average daily volume of 793,100 shares, the short-interest ratio is presently 5.2 days.December 30, 2024 | marketbeat.comADC Therapeutics completes enrollment in LOTIS-5 trialDecember 30, 2024 | markets.businessinsider.comADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell LymphomaDecember 30, 2024 | prnewswire.comADC Therapeutics SA (NYSE:ADCT) Major Shareholder Purchases $304,000.00 in StockDecember 14, 2024 | insidertrades.comRedmile Group, LLC Increases Stake in ADC Therapeutics SADecember 13, 2024 | gurufocus.comRedmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) StockADC Therapeutics SA (NYSE:ADCT - Get Free Report) major shareholder Redmile Group, Llc purchased 100,000 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was bought at an average cost of $3.04 per share, with a total value of $304,000.00. Following the purchase, the insider now owns 13,145,712 shares in the company, valued at approximately $39,962,964.48. This represents a 0.77 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.December 13, 2024 | marketbeat.comAnalysts Set Expectations for ADCT FY2024 EarningsADC Therapeutics SA (NYSE:ADCT - Free Report) - Equities researchers at HC Wainwright issued their FY2024 earnings per share estimates for ADC Therapeutics in a report released on Wednesday, December 11th. HC Wainwright analyst R. Burns anticipates that the company will earn ($1.75) per share forDecember 13, 2024 | marketbeat.comADC Therapeutics announces data from LOTIS-7 Phase 1b open-label clinical trialDecember 12, 2024 | markets.businessinsider.comADC Therapeutics falls -8.9%December 12, 2024 | markets.businessinsider.comPromising Efficacy in LOTIS-7 Trial Boosts Buy Rating for ADC TherapeuticsDecember 12, 2024 | markets.businessinsider.comADC Therapeutics SA Common Shares (ADCT) Insider ActivityDecember 11, 2024 | nasdaq.comADC Therapeutics stock plunges 36% amid Zynlonta data releaseDecember 11, 2024 | msn.comADC Teeters on Trial DataDecember 11, 2024 | baystreet.caADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaDecember 11, 2024 | prnewswire.comADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular LymphomaDecember 9, 2024 | prnewswire.comInsider Selling: ADC Therapeutics SA (NYSE:ADCT) Major Shareholder Sells 25,352 Shares of StockADC Therapeutics SA (NYSE:ADCT - Get Free Report) major shareholder Redmile Group, Llc sold 25,352 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $2.07, for a total value of $52,478.64. Following the completion of the sale, the insider now owns 15,566,731 shares of the company's stock, valued at approximately $32,223,133.17. This trade represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.December 6, 2024 | marketbeat.comADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical TrialDecember 6, 2024 | prnewswire.comADC Therapeutics SA (NYSE:ADCT) Shares Bought by Redmile Group LLCRedmile Group LLC raised its holdings in ADC Therapeutics SA (NYSE:ADCT - Free Report) by 2.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,669,217 shares of the company's stock after acquiring an additionalDecember 5, 2024 | marketbeat.comADC Therapeutics Makes Grants to New Employees Under Inducement PlanDecember 2, 2024 | prnewswire.comShort Interest in ADC Therapeutics SA (NYSE:ADCT) Declines By 9.7%ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,170,000 shares, a decrease of 9.7% from the October 15th total of 3,510,000 shares. Based on an average daily volume of 355,600 shares, the short-interest ratio is currently 8.9 days.November 19, 2024 | marketbeat.comADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comADC Therapeutics Highlights Q3 Advances and Strategic FocusNovember 10, 2024 | markets.businessinsider.comADC Therapeutics SA (ADCT) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comStephens & Co. Initiates Coverage of ADC Therapeutics (ADCT) with Overweight RecommendationNovember 9, 2024 | msn.comADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of ADC Therapeutics SA (NYSE:ADCT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating tNovember 8, 2024 | marketbeat.comStephens Initiates Coverage on ADC Therapeutics (NYSE:ADCT)Stephens began coverage on shares of ADC Therapeutics in a research report on Friday. They set an "overweight" rating and a $6.00 target price for the company.November 8, 2024 | marketbeat.comADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational UpdateNovember 7, 2024 | prnewswire.comADC Therapeutics's Earnings: A PreviewNovember 6, 2024 | benzinga.comADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual MeetingNovember 5, 2024 | prnewswire.comADC Therapeutics to Present at November Investor ConferencesNovember 4, 2024 | prnewswire.com Remove Ads Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address ADCT Media Mentions By Week ADCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADCT News Sentiment▼0.570.71▲Average Medical News Sentiment ADCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADCT Articles This Week▼42▲ADCT Articles Average Week Remove Ads Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABUS News BCYC News DNTH News KURA News CDXC News KALV News MGTX News VALN News IMTX News PHAR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ADCT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
